GlobalData on MSN7h
Novo Nordisk strikes $1bn deal for Lexicon’s oral obesity drug
Novo Nordisk has signed a deal worth up to $1bn with Lexicon Pharmaceuticals for the exclusive global rights to LX9851, an ...
Novo Nordisk’s $2B deal for obesity drug a strategic game-changer for US pharmaceutical market
Danish pharmaceutical company Novo Nordisk — best known for its blockbuster weight-loss drugs Ozempic and Wegovy — has signed ...
BioSpace11h
Novo’s Obesity Pipeline Keeps Evolving With up to $1B Lexicon Deal
Lexicon's LX9851 targets ACSL5, a liver enzyme involved in fat metabolism that helps moderate fat accumulation and slow down ...
PharmExec10h
Novo Nordisk Reaches Licensing Deal with Lexicon Pharmaceuticals for Novel Obesity Candidate
Under terms of the deal, Novo Nordisk will obtain global rights to develop, manufacture, and commercialize LX9851 for obesity ...
‘There's a huge percentage of the US population that isn't getting access to these medications’: Novo Nordisk makes game-changing $2 billion deal for new obesity d…
Danish pharmaceutical company Novo Nordisk — best known for its blockbuster weight-loss drugs Ozempic and Wegovy — has signed ...
Jefferies Sticks to Their Buy Rating for The United Laboratories International Holdings (ULIHF)
In a report released yesterday, David Shang from Jefferies maintained a Buy rating on The United Laboratories International Holdings (ULIHF – ...
Explore more
Contract Pharma10h
Novo Nordisk Enters Exclusive License Agreement with Lexicon for LX9851
Novo Nordisk has entered into an exclusive license agreement with Lexicon Pharmaceuticals Inc. for LX9851, a first-in-class, ...
J.P. Morgan Keeps Their Buy Rating on Novo Nordisk (0QIU)
J.P. Morgan analyst Richard Vosser maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of ...